This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Cleerly, a digital healthcare company focused on heart disease, has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal CardiovascularImaging. Eur Heart J Cardiovasc Imaging. Barcelona, Spain.
The Cleerly ISCHEMIA software provides noninvasive estimates of FFR values that help healthcare professionals make critical decisions in the management of patients with suspected coronaryarterydisease," said James P. "The in European Association of CardiovascularImaging: Late Breaking Clinical Research and Trials.
Christian Tesche (Division of CardiovascularImaging, Department of Radiology and Radiological Science, Medical University of South Carolina and Department of Cardiology, Munich University Clinic, Ludwig-Maximilian-University).
milla1cf Thu, 03/28/2024 - 07:00 March 28, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: CardiovascularImaging on March 13, 2024.
Attendees can join with their peers and participate in sessions on structural heart disease, congenital heart disease, guidelines and trials, AI/Machine learning, technical aspects of cardiac CT, coronaryarterydisease, vascular heart disease, debates and games and early career topics. for all attendees.
mmol/l (130 mg/dl) or below, between 20-50% will already have coronaryarterydisease. As HBA1c increases, even in the normal range, the probability of coronaryarterydisease increases. For HBA1c, the trend is similar. Remember, these are all in the ‘normal’ range. JAMA Cardiol.
Circulation: CardiovascularImaging, Ahead of Print. The clinical spectrum of radiation-induced cardiovascular toxicity is broad, encompassing coronaryarterydisease, myocardial dysfunction, valvular abnormalities, and pericardial disorders.
A multimodality imaging approach to differentiate physiological changes due to athlete’s heart from significant cardiac ailment has been suggested by an expert consensus from the European Association of CardiovascularImaging. These are useful in suspected myocardial diseases like cardiomyopathy and myocarditis.
Together, the two companies will work to further the development and commercialization of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare’s interventional cardiology portfolio built around the Allia Platform.
The relationship is simple—higher cholesterol for longer increases your risk of coronaryarterydisease 4. The best cholesterol value in the standard cholesterol panel to evaluate the risk of coronaryarterydisease is your Non-HDL. 6, 2017 7 JACC: CardiovascularImaging May 2015, 8 (5) 579-596;
Cleerly is dedicated to creating a new standard of care for heart disease by using FDA-cleared solutions powered by artificial intelligence. Cleerly’s pioneering approach to advanced cardiovascularimaging, powered by AI-driven analysis, is elevating the field of diagnostic tools for coronaryarterydisease.
mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovasculardisease. mg improved several measures of plaque volume changes over a period of 12 months in patients with stable coronaryarterydisease, Dr. Budoff continued.
Image courtesy: Philips christine.book Wed, 06/12/2024 - 14:07 June 12, 2024 — Royal Philips has announced its next-generation AI-enabled cardiovascular ultrasound platform to help speed up cardiac ultrasound analysis with proven AI technology and reduce the burden on echocardiography labs.
I think especially with the recent changes in guidelines and the recommendation to use CT for screening of coronaryarterydisease, we expect to see this trend really impact the way CT is used in the future.” “The CT procedural mix is evolving, and cardiac CT is starting to account for a large proportion of that.
mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovasculardisease. mg improved several measures of plaque volume changes over a period of 12 months in patients with stable coronaryarterydisease, Dr. Budoff continued.
a leader in non-invasive artificial intelligence (AI) heart care solutions, announced that the data from its REVEALPLAQUE study , highlighting the accuracy of its Plaque Analysis, was published in the European Heart Journal CardiovascularImaging. milla1cf Thu, 05/23/2024 - 08:00 May 23, 2024 — HeartFlow, Inc. ,
If a parent or an uncle had coronaryartery bypass surgery at age 50 and then died suddenly with a heart attack being shown at autopsy, then you can be pretty certain coronaryarterydisease was the cause. Most of the time, coronaryarterydisease will be the cause. But not always.
Circulation: CardiovascularImaging, Volume 17, Issue 2 , Page e016178, February 1, 2024. Women were older (median age, 71 versus 65 years;P<0.001) and had less severe coronaryarterydisease with a lower plaque burden than men. Hounsfield units; moderate inflammation, −73.0 Hounsfield units).RESULTS:A
Circulation: CardiovascularImaging, Volume 17, Issue 1 , Page e015858, January 1, 2024. BACKGROUND:Advanced chronic kidney disease is associated with high cardiovascular risk, even after kidney transplant. Normal PET was associated with the lowest risk of MACE (2.2%/year year versus 3.6%/year
Circulation: CardiovascularImaging, Volume 17, Issue 2 , Page e016057, February 1, 2024. BACKGROUND:Sex-specific differences in coronary phenotypes in response to stress have not been elucidated.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content